SERPINx will be participating in the 2019 New York Venture Summit on July 9-10th in New York. Roger Legtenberg, our CEO, looks forward to meet with you and discuss our platform technology of modified SERPINs & our lead program (SPx-001), currently in development as gene therapy for Heriditary Angioedema.